Molina Healthcare (MOH) is back in focus after third quarter 2026 results showed lower revenue and profit than a year earlier, alongside updated 2026 guidance and fresh 2027 premium revenue targets.
The recent update has come after a choppy stretch for Molina Healthcare’s stock, with a 7.3% 1 month share price return and a 14.75% year to date share price return, set against a weaker 3 year total shareholder return that has declined 37.56%. This suggests that short term momentum has picked up even as longer term holders have seen value erode.
Scan how Molina Healthcare stacks up against other managed care and defensive health insurers by checking a curated group of list of solid balance sheet and fundamentals (24 results).
Molina Healthcare now trades higher following weaker recent earnings and new premium revenue targets. Does that combination still leave the risk reward tilted toward buyers when compared with today's valuation?
Most Popular Narrative: 5% Undervalued
Molina Healthcare’s most followed narrative anchors fair value at $216.29 per share versus a last close of $204.79, which frames the current risk reward debate around modest implied upside and execution on Medicaid and Marketplace plans.
Already won Medicaid contracts and embedded revenue, including large programs in Florida, Georgia, Texas and Illinois, together with management’s plan to reach $64b of premium by 2029 from $42b in 2026, describe a pipeline of growth that can feed revenue and earnings without relying solely on new wins.
See why 64 investors see Molina Healthcare as 5% undervalued.
The narrative applies a 7.31% discount rate to those projected premiums and earnings, then arrives at a fair value that sits only slightly above both the current share price and the latest analyst consensus target. That keeps attention firmly on whether Medicaid margin recovery, the exit from loss making Medicare Advantage products, and a smaller but more focused ACA Marketplace book can collectively support the margin and earnings path implied in the models.
Result: Fair Value of $216.29 (UNDERVALUED)
Still, Medicaid funding changes or further ACA Marketplace strain could quickly challenge Molina Healthcare’s margin recovery story and reshape how investors view that 5% undervaluation gap.
Find out about the key risks to this Molina Healthcare narrative.
Next Steps
Sentiment in this Molina Healthcare story leans cautious, so move quickly and pressure test the thesis against the data yourself before drawing a line in the sand. To see which positives analysts are focused on and decide how compelling they really are for your own portfolio, review the 3 key rewards
Looking for more investment ideas beyond Molina Healthcare?
If Molina Healthcare has sharpened your thinking, do not stop here. Broader context across sectors can help you spot opportunities that better match your risk comfort.
- Target durable balance sheets and steadier fundamentals by scanning a curated list of solid balance sheet and fundamentals (24 results) that filters for financial strength and resilience.
- Hunt for quality at a discount by reviewing a focused 29 high quality undervalued stocks that highlights companies where fundamentals and current pricing may be misaligned.
- Build a cash flow focused watchlist by checking a hand picked 5 dividend fortresses that concentrates on higher yielding businesses with meaningful payouts.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com